Filing Summary
vTv Therapeutics Inc. (Nasdaq: VTVT) filed this Form 8-K regarding corporate governance changes. The Board approved the changes on October 1, 2026; the report was signed on October 6, 2026.
Financial and Operating Information
This filing reports no revenue, earnings, cash flow, margin, debt, liquidity, or other operating or financial metrics. It does not provide financial guidance or an outlook.
Material Changes
The Board adopted the Company’s Third Amended and Restated By-Laws. Changes include:
- Additional requirements for director nominations, including evidence of compliance with Exchange Act Rule 14a-19 due no later than five business days before the stockholder meeting.
- A revised voting standard: for matters other than director elections, approval generally requires a majority of votes cast for or against, subject to specified exceptions.
- Updates to stockholder-meeting procedures to conform to Delaware law.
- U.S. federal district courts designated as the exclusive forum for Securities Act claims, unless the Company consents in writing to another forum.
Risks, Contingencies, and Items to Verify
- Review Exhibit 3.1, the full amended bylaws, for the complete nomination, voting, meeting, and forum-selection provisions.
- Consider the practical implications of the Securities Act forum-selection clause and the exceptions to the revised voting standard.
The filing does not describe financial contingencies or unusual financial items.